Executive Incentives Through Share-Price-Linked Stock Options
First written in FY2019. 6 of 9 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2024.
Seiren moved to the "Worse" side of this theme in 2024.
3 other companies' latest entry also says "Reframed".
- FY2024ReframedAnnual report
「Share-based compensation will generally consist of restricted stock compensation. For domestic nonresidents for whom it is difficult to grant restricted stock, share-price-linked cash compensation (phantom stock) will be granted as a substitute.」
The company is reorganizing the program from one centered on stock options to one based primarily on restricted stock compensation, with phantom stock used for domestic nonresidents. - FY2023AdvancedAnnual report
「Other (disposal of treasury shares under the restricted stock compensation plan) 71,400」
Under the program transitioned from stock options to restricted stock compensation, the company disposed of 71,400 treasury shares during the fiscal year. - FY2022ReframedAnnual report
「At the 150th Annual General Meeting of Shareholders held on 21 June 2022, a resolution was passed to introduce a restricted stock compensation plan in place of the stock option-based share compensation plan.」
The company resolved to change the program from one based on continuing share-price-linked stock options to one based on restricted stock compensation. - FY2022-Q2AdvancedAnnual report
「Number of share acquisition rights (units)* 1,163 (Note 1) Class, description and number of shares underlying the share acquisition rights (shares)* Common shares 116,300 (Note 1) Exercise period for the share acquisition rights* 9 July 2021 to 8 July 2061」
For the share-price-linked stock options approved on 23 June 2021, the company disclosed the 1,163 share acquisition rights issued, the 116,300 shares covered and the exercise period. - FY2021AdvancedAnnual report
「SEIREN CO.,LTD. eighth series of share acquisition rights. Total number of share acquisition rights: 1,928; common shares: 192,800. Exercise period for the share acquisition rights: 9 July 2021 to 8 July 2061.」
Regarding the program designed to share the benefits and risks of share-price movements with shareholders and increase motivation to contribute to enhanced corporate value, the company approved the issuance of the eighth series of share acquisition rights and specified the number of shares covered and the exercise period. - FY2021-Q2AdvancedAnnual report
「Number of share acquisition rights (units)* 1,620 (Note 1) Class, description and number of shares underlying the share acquisition rights (shares)* Common shares 162,000 (Note 1) Exercise period for the share acquisition rights* 17 August 2020 to 16 August 2060」
For the share-price-linked stock options approved on 19 June 2020, 1,620 share acquisition rights covering 162,000 common shares were issued. - FY2020AdvancedAnnual report
「The matters approved at the Board of Directors meeting held on 19 June 2020 are as follows.」
The company approved the issuance of the seventh series of share acquisition rights covering 2,297 rights and 229,700 common shares, with an exercise period from 17 August 2020 to 16 August 2060. The company continues and expands the program designed to increase motivation to contribute to a higher share price and enhanced corporate value. - FY2020-Q2AdvancedAnnual report
「Number of share acquisition rights (units)* 1,274 (Note 1) Class, description and number of shares underlying the share acquisition rights (shares)* Common shares 127,400 (Note 1) Exercise period for the share acquisition rights* 9 July 2019 to 8 July 2059」
For the share-price-linked stock options approved on 20 June 2019, 1,274 share acquisition rights covering 127,400 shares were granted, and the exercise period also began. - FY2019First statedAnnual report
「The purpose is to share with shareholders the benefits and risks of share-price movements and further increase directors’ motivation to contribute to higher share prices and corporate value.」
The Company planned to issue the sixth series of stock acquisition rights covering 205,800 common shares to directors and executive officers, positioning the rights as an incentive to increase the share price and corporate value.